NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ANIP Stock Alerts $69.13 -0.56 (-0.80%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$69.00▼$70.0550-Day Range$54.20▼$69.6952-Week Range$36.99▼$70.81Volume252,152 shsAverage Volume136,027 shsMarket Capitalization$1.46 billionP/E Ratio82.30Dividend YieldN/APrice Target$80.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get ANI Pharmaceuticals alerts: Email Address ANI Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside15.7% Upside$80.00 Price TargetShort InterestHealthy1.24% of Shares Sold ShortDividend StrengthN/ASustainability-2.48Upright™ Environmental ScoreNews Sentiment0.20Based on 7 Articles This WeekInsider TradingSelling Shares$7.94 M Sold Last QuarterProj. Earnings Growth16.62%From $3.55 to $4.14 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.80 out of 5 starsMedical Sector48th out of 938 stocksPharmaceutical Preparations Industry21st out of 425 stocks 2.5 Analyst's Opinion Consensus RatingANI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $80.00, ANI Pharmaceuticals has a forecasted upside of 15.7% from its current price of $69.13.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.24% of the outstanding shares of ANI Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ANI Pharmaceuticals has recently increased by 5.02%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreANI Pharmaceuticals has received a 36.91% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Beta blockers (C07)", "Macrolides", "Antifungal medication (D01) ", "Cyclophosphamide", and "Calcium channel blockers (C08)" products. See details.Environmental SustainabilityThe Environmental Impact score for ANI Pharmaceuticals is -2.48. Previous Next 2.9 News and Social Media Coverage News SentimentANI Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ANI Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest14 people have searched for ANIP on MarketBeat in the last 30 days. This is an increase of 1,300% compared to the previous 30 days.MarketBeat Follows10 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,943,477.00 in company stock.Percentage Held by Insiders28.50% of the stock of ANI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 16.62% in the coming year, from $3.55 to $4.14 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 82.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.63.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 82.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 218.08.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About ANI Pharmaceuticals Stock (NASDAQ:ANIP)ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Read More ANIP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIP Stock News HeadlinesMarch 17, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 10,093 SharesMarch 12, 2024 | insidertrades.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CFO Sells 7,787 Shares of StockMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 11, 2024 | insidertrades.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 16,292 SharesMarch 11, 2024 | insidertrades.comInsider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Sells 28,965 Shares of StockMarch 27, 2024 | globenewswire.comANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USPMarch 27, 2024 | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) Reaches New 12-Month High at $70.81March 23, 2024 | finance.yahoo.comNYCB, Vista Outdoor, Cardlytics, and More Stocks See Action From Activist InvestorsMarch 28, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 21, 2024 | finance.yahoo.comANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should KnowMarch 19, 2024 | money.usnews.comANI Pharmaceuticals IncMarch 18, 2024 | americanbankingnews.comShort Interest in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Rises By 16.7%March 18, 2024 | americanbankingnews.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $80.00 Consensus Price Target from BrokeragesMarch 14, 2024 | stocknews.com3 Biotech Stocks to Jumpstart Your Portfolio GainsMarch 12, 2024 | benzinga.comANI Pharmaceuticals SVP & CFO Sold $510K In Company StockMarch 9, 2024 | finance.yahoo.comANI Pharmaceuticals Inc CEO Nikhil Lalwani Sells 45,257 SharesMarch 7, 2024 | finance.yahoo.comDirector Antonio Pera Sells 7,000 Shares of ANI Pharmaceuticals Inc (ANIP)March 6, 2024 | markets.businessinsider.comExpert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 AnalystsMarch 5, 2024 | realmoney.thestreet.comANI Pharmaceuticals price target raised by $7 at Guggenheim, here's whyMarch 5, 2024 | markets.businessinsider.comANI Pharmaceuticals Outperforms with Strong Cortrophin Sales and Solid Generics Business GrowthMarch 3, 2024 | finance.yahoo.comAn Intrinsic Calculation For ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Suggests It's 48% UndervaluedMarch 3, 2024 | investing.comEarnings call: ANI Pharmaceuticals sees robust growth in Q4 2023March 2, 2024 | seekingalpha.comANI Pharmaceuticals, Inc. (ANIP) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finanznachrichten.deANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 GuidanceFebruary 29, 2024 | washingtonpost.comANI: Q4 Earnings SnapshotFebruary 29, 2024 | markets.businessinsider.comANI Pharmaceuticals Q4 Profit Tops Estimates; Revenues Up 39.7%See More Headlines Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/29/2024Today3/28/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CUSIPN/A CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees642Year FoundedN/APrice Target and Rating Average Stock Price Target$80.00 High Stock Price Target$83.00 Low Stock Price Target$77.00 Potential Upside/Downside+15.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.84 Trailing P/E Ratio82.30 Forward P/E Ratio19.47 P/E GrowthN/ANet Income$18.78 million Net Margins3.86% Pretax Margin4.08% Return on Equity18.06% Return on Assets8.38% Debt Debt-to-Equity Ratio0.66 Current Ratio3.57 Quick Ratio2.81 Sales & Book Value Annual Sales$486.82 million Price / Sales2.99 Cash Flow$6.38 per share Price / Cash Flow10.84 Book Value$21.13 per share Price / Book3.27Miscellaneous Outstanding Shares21,080,000Free Float15,071,000Market Cap$1.46 billion OptionableOptionable Beta0.80 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Nikhil Lalwani (Age 46)President, CEO & Director Comp: $1.31MMr. Stephen P. Carey (Age 53)Senior VP of Finance & CFO Comp: $751kMr. James G. Marken (Age 61)Senior Vice President of Operations & Product Development Comp: $673.23kMr. Christopher K. Mutz (Age 52)Head of Rare Disease Comp: $565.17kMr. Ori Gutwerg (Age 50)Senior Vice President of Generics Comp: $623.89kMr. Muthusamy Shanmugam MS R.Ph. (Age 56)Head of R&D, COO of Novitium Operations & Director Ms. Meredith W. Cook (Age 50)Senior VP, General Counsel & Corporate Secretary Mr. Chad Gassert (Age 48)Senior Vice President of Corporate Development & Strategy Ms. Krista L. Davis (Age 51)Chief Human Resources Officer Ms. Elizabeth Powell J.D.Chief Compliance Officer & Head of Legal of Rare DiseaseMore ExecutivesKey CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLDisc MedicineNASDAQ:IRONArcus BiosciencesNYSE:RCUSKiniksa PharmaceuticalsNASDAQ:KNSAImmunomeNASDAQ:IMNMView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 355 shares on 3/22/2024Ownership: 0.029%Vanguard Group Inc.Bought 156,594 shares on 3/11/2024Ownership: 6.115%Stephen P CareySold 7,787 sharesTotal: $510,437.85 ($65.55/share)Nikhil LalwaniSold 16,292 sharesTotal: $1.09 M ($67.13/share)Muthusamy ShanmugamSold 15,085 sharesTotal: $1.00 M ($66.35/share)View All Insider TransactionsView All Institutional Transactions ANIP Stock Analysis - Frequently Asked Questions Should I buy or sell ANI Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANIP shares. View ANIP analyst ratings or view top-rated stocks. What is ANI Pharmaceuticals' stock price target for 2024? 4 brokerages have issued 1 year price targets for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $77.00 to $83.00. On average, they predict the company's share price to reach $80.00 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View analysts price targets for ANIP or view top-rated stocks among Wall Street analysts. How have ANIP shares performed in 2024? ANI Pharmaceuticals' stock was trading at $55.14 at the beginning of the year. Since then, ANIP shares have increased by 25.4% and is now trading at $69.13. View the best growth stocks for 2024 here. Are investors shorting ANI Pharmaceuticals? ANI Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totaling 261,600 shares, an increase of 5.0% from the February 29th total of 249,100 shares. Based on an average daily volume of 134,700 shares, the days-to-cover ratio is currently 1.9 days. View ANI Pharmaceuticals' Short Interest. When is ANI Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ANIP earnings forecast. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) released its quarterly earnings results on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a trailing twelve-month return on equity of 18.06% and a net margin of 3.86%. What ETFs hold ANI Pharmaceuticals' stock? ETFs with the largest weight of ANI Pharmaceuticals (NASDAQ:ANIP) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What guidance has ANI Pharmaceuticals issued on next quarter's earnings? ANI Pharmaceuticals issued an update on its FY24 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of $4.26-4.67 for the period, compared to the consensus earnings per share estimate of $4.46. The company issued revenue guidance of $520-542 million, compared to the consensus revenue estimate of $535.21 million. What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO? 5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC). Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (6.31%), Vanguard Group Inc. (6.11%), Rubric Capital Management LP (5.50%), Dimensional Fund Advisors LP (2.89%), Global Alpha Capital Management Ltd. (2.85%) and Ranger Investment Management L.P. (2.13%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Stephen P Carey and Thomas Haughey. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANIP) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.